StockData

Myriad Genetics vs QuidelOrtho

MYGN and QDEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MYGN and QDEL compare

QuidelOrtho is the larger company, worth 1.3 times as much as Myriad Genetics ($677M against $530M).

Myriad Genetics grew revenue faster over the last twelve months (−3.2% versus −4.5% for QuidelOrtho).

Myriad Genetics keeps more of each dollar of sales as profit, with a net margin of −14.0% compared with −14.2% at QuidelOrtho.

Myriad Genetics scores higher on the StockData Score (8 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMYGNQDEL
Size and price
Market cap$530M$677M
Share price$5.54$9.87
Change, 1 year−17.4%−53.7%
Change, 5 years−79.2%−93.2%
Beta (5Y)−0.091.32
Employees2,7006,500
StockData Score
Total score8 (better)6
Valuation score33
Growth score00
Performance score3 (better)2
Health score2 (better)1
Dividend score00
Valuation
P/S0.7×0.3× (better)
P/B1.7×0.4× (better)
EV/EBITDA–10.3×
FCF yield–−17.3%
Fair value$18.25$26.64
Margin of safety69.6% (better)63.0%
Growth
Revenue growth (TTM)−3.2% (better)−4.5%
Revenue growth, 5Y average−0.63%10.4% (better)
Profitability
Gross margin68.8% (better)44.2%
Operating margin−12.2%−4.9% (better)
Net margin−14.0% (better)−14.2%
FCF margin–−4.5%
Return on equity−32.5%−19.3% (better)
Return on invested capital−22.8%−2.2% (better)
Financial health
Debt / equity0.40 (better)1.64
Net debt / EBITDA–8.29
Interest coverage−6.0×−0.6× (better)
Current ratio2.21 (better)1.36
Altman Z-score−0.630.26 (better)
Piotroski F-score56 (better)
Dividends and buybacks
Buyback yield–−0.66%
Shareholder yield0.00% (better)−0.66%
Ownership
Held by institutions94.1%121%
Held by insiders7.2%43.4%
Insider net buying, 12 months$655K$669K (better)
Short interest, % of float9.5%37.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.